NCT05002270
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express a KRAS G12C mutation
Exclusions: Patients who have not received at least 1 prior standard therapy; Patients with untreated symptomatic brain or spinal metastases – see trial for details
https://ClinicalTrials.gov/show/NCT05002270